Latest guidelines for use of antiplatets and anticoagulants in different conditions , for primary prevention , secondary prevention , in cardiovascular diseases like CVA , ACS, PAD.. according to latest guidelines and latest textbooks .. give mnemonices wherever possible ( mnemonics should be medically relevant and easily recallable. )

Reading File

Finding Sources

Searching PubMed

antiplatelet anticoagulant guidelines cardiovascular prevention

Searching the Web

ACC AHA ESC 2024 2025 antiplatelet anticoagulant guidelines ACS CVA PAD primary secondary prevention

Reading File

Finding Sources

Reading Web Page

https://www.sciencedirect.com/science/article/abs/pii/S07351…

Reading File

Finding Sources

Searching PubMed

antiplatelet therapy peripheral artery disease guidelines 2024

Reading File

Reading Article

PMID: 38104631

Reading Article

PMID: 38752899

Searching the Web

2024 2025 ACC AHA stroke TIA antiplatelet guidelines aspirin clopidogrel ticagrelor dual POINT CHANCE

Latest guidelines for use of antiplatets and anticoagulants in different conditions , for primary prevention , secondary prevention , in cardiovascular diseases like CVA , ACS, PAD.. according to latest guidelines and latest textbooks ..also tell what has changed in latest guidelines from previous years text ..give mnemonices wherever possible ( mnemonics should be medically relevant and easily recallable. )

Antiplatelets & Anticoagulants: Comprehensive Clinical Guide

Based on: Harrison's 22E (2025), Goldman-Cecil, Braunwald's Heart Disease, Fuster & Hurst, Adams & Victor's Neurology | 2025 ACC/AHA ACS, 2024 ACC/AHA PAD, 2026 AHA/ASA Stroke, 2024 ESC CCS Guidelines

QUICK PHARMACOLOGY ORIENTATION

Antiplatelet Agents - "PAT CAVED"

Letter	Drug	Mechanism
P	Prostacyclin analogues (iloprost)	PGI2 mimetic, vasodilatory
A	Aspirin (ASA)	COX-1 inhibitor → ↓TXA2 (irreversible)
T	Ticagrelor / Ticlopidine	P2Y12 ADP-receptor blocker (reversible / irreversible)
C	Clopidogrel / Cangrelor	P2Y12 ADP-receptor blocker (irreversible/IV)
A	Abciximab / Eptifibatide / Tirofiban	GPIIb/IIIa inhibitors
V	Vorapaxar	PAR-1 (thrombin receptor) blocker
E	Extended-release Dipyridamole	PDE inhibitor → ↑cAMP → ↓platelet activation
D	Dual pathway (ASA + Rivaroxaban 2.5mg)	Antithrombotic combination

Mnemonic for P2Y12 drugs: "CAT PRaTicle" = Cangrelor (IV), ASP (aspirin co-drug), Ticagrelor, Prasugrel, Ticlopidine (obsolete)

Anticoagulant Agents - "HALF DAB"

Letter	Drug	Target
H	Heparin (UFH)	IIa + Xa (via antithrombin)
A	Argatroban / Bivalirudin	Direct thrombin (IIa) inhibitors
L	LMWH (enoxaparin, dalteparin)	Xa >> IIa
F	Fondaparinux	Xa only (indirect, via AT)
D	Dabigatran	Direct thrombin (IIa) inhibitor - oral
A	Apixaban / Edoxaban	Direct factor Xa inhibitors - oral
B	Bivalirudin / Betrixaban	Direct IIa / Xa

DOAC mnemonic: "3 Xabans + 1 gatran" = Rivaroxaban, Apixaban, Edoxaban (Xa) + Dabigatran (IIa). Remember "RivAEd gAtran"

SECTION 1: PRIMARY PREVENTION

Who Should Get Aspirin for Primary Prevention?

Mnemonic: "ASPIRIN PRIMARY = NOT routine anymore - CHECK the 3 Cs"

Calculate 10-year ASCVD risk (use pooled cohort equations)
Consider age (stop recommending after age 60-70)
Contraindicate if high bleeding risk

2025/2026 Guidelines vs. Previous

Parameter	Old Recommendation (pre-2022)	Current (2025-2026)
Aspirin for 1° prevention, age 40-59	Recommended if 10-yr risk ≥10%	Still acceptable (Class IIb) IF 10-yr CVD risk ≥10% AND low bleeding risk (ACC/AHA 2025)
Aspirin for 1° prevention, age ≥60	Debated	NOT recommended - AHA 2022 USPSTF, affirmed 2025: benefit does NOT outweigh bleeding risk
Aspirin for 1° prevention, age ≥70	Routine use	Explicitly contraindicated - Goldman-Cecil Medicine: "prophylactic aspirin is NOT recommended for primary prevention in adults over age 70 years"
Statin in 1° prevention	At risk only	Still cornerstone; aspirin is ADD-ON only if risk ≥10%

Key 1° Prevention Studies Changed the Landscape:

ARRIVE (2018): No benefit in moderate risk patients
ASCEND (2018): Benefit in diabetics but offset by bleeding
ASPREE (2018): Harm in elderly >70 years

All three trials published ~2018 collectively drove the 2022 USPSTF and subsequent guideline revision

Mnemonic for When to Use Aspirin in 1° Prevention: "BLEED or LEAD"

B - Bleeding risk HIGH? → Stop/avoid
L - Low risk patient (<10% 10-yr ASCVD)? → No benefit
E - Elderly (>60-70 yrs)? → No longer recommended
E - Evidence insufficient below age 40? → Don't start
D - Diabetes + ≥10% risk + age 40-59? → May consider (IIb)

SECTION 2: ACUTE CORONARY SYNDROME (ACS)

Core Principle: DAPT = Aspirin + P2Y12 inhibitor

Mnemonic for ACS Antiplatelet Strategy: "LOAD AT once, MAINTAIN for a year"

2025 ACC/AHA ACS Guideline (Key Antithrombotic Recommendations)

A. Loading Dose

Drug	Loading Dose	Maintenance
Aspirin	162-325 mg oral (chewed)	81 mg daily
Ticagrelor	180 mg	90 mg BID
Prasugrel	60 mg	10 mg daily (5 mg if <60kg or age >75)
Clopidogrel	600 mg (PCI) or 300 mg	75 mg daily

B. P2Y12 Choice - "TaP Beats Clop" (Ticagrelor and Prasugrel Beat Clopidogrel)

Ticagrelor or Prasugrel preferred over Clopidogrel in ACS undergoing PCI (Class I, LOE B) - 2025 ACC/AHA
ESC 2023: Prasugrel preferred over Ticagrelor in PCI (Class IIa) - slight difference from ACC/AHA
Clopidogrel used when: Ticagrelor/Prasugrel contraindicated, OR high bleeding risk, OR patient already on oral anticoagulant

C. DAPT Duration - Mnemonic: "DEFAULT 12, BLEED 1-3, EXTEND if HIGH RISK"

Scenario	Duration	Guideline
Default post-ACS/PCI	12 months (Class I)	2025 ACC/AHA
High bleeding risk (HBR)	1-3 months, then monotherapy	2025 ACC/AHA
Low ischemic risk	De-escalate to monotherapy (P2Y12i alone) at 3-6 months	Class IIa, 2025 ACC/AHA
High ischemic risk (DM, prior MI, renal failure, stent thrombosis)	>12 months (extend DAPT)	Class IIa
ESC 2023 (major change)	P2Y12 monotherapy after only 1 month (Class IA)	More aggressive de-escalation

KEY CHANGE 2025 vs older guidelines: ESC introduced the possibility of P2Y12 monotherapy after just 1 month post-PCI (ticagrelor or prasugrel alone after dropping aspirin) - this is more aggressive than previous ESC and current ACC/AHA positions

D. Anticoagulation in ACS (Acute Phase)

Mnemonic: "UFH for Cath, LMWH for Medical, Fonda for NSTEMI"

Agent	Setting	Notes
UFH	PCI (preferred periprocedurally)	Weight-based; reversible with protamine
Bivalirudin	PCI (alternative to UFH)	Direct thrombin inhibitor; less HIT risk
Enoxaparin (LMWH)	Medical management NSTEMI	1 mg/kg SC BID; avoid if eGFR <15
Fondaparinux	NSTEMI medically managed	2.5 mg SC daily; least bleeding risk
Prasugrel	AVOID if prior TIA/stroke	Absolute contraindication

E. Triple Therapy (ACS + Atrial Fibrillation needing OAC)

Mnemonic: "Triple → Double → Single: The TAD-DOWN Rule"

Triple (ASA + P2Y12 + OAC): Maximum 1 week (up to 1 month only if very high thrombotic risk)
Double (P2Y12 (clopidogrel preferred) + OAC): Continue up to 6-12 months (CCS) or 12 months (ACS)
Alone (OAC only): Long-term after completing dual therapy
P2Y12 of choice in triple/dual therapy = Clopidogrel (not prasugrel/ticagrelor - higher bleeding)
DOAC preferred over warfarin (AUGUSTUS, ENTRUST-AF PCI trials)
Sources: Fuster & Hurst 15E, Goldman-Cecil, 2024 ESC CCS

What Changed from Previous ACS Guidelines?

Topic	Previous (Pre-2023)	Current (2025 ACC/AHA + 2023 ESC)
P2Y12 pre-treatment	Routine before angio	No routine pre-treatment if anatomy unknown (Class III harm for prasugrel before angio)
DAPT de-escalation	Not well-defined	Now explicitly Class IIa: guided by platelet function test OR unguided de-escalation both acceptable
Cangrelor	Rarely mentioned	Indicated for PCI when no oral P2Y12 given: IV bridging (Class IIa)
ESC: P2Y12 monotherapy	After 6-12 months	Now after 1 month (Class IA) - major shift
Complete revascularization	Staged preferred	Now acceptable to do complete revascularization at index PCI in hemodynamically stable STEMI (Class IIa)
Anticoagulation post-ACS	UFH standard	Bivalirudin now equivalent alternative with lower bleeding (Class IIa)

SECTION 3: CHRONIC CORONARY SYNDROME (CCS) / STABLE CAD

Mnemonic: "Single Aspirin Stays; Add Second if RISKY"

Standard: Aspirin 81 mg daily for life (Class I) Second antithrombotic agent - consider if HIGH ISCHEMIC risk + LOW bleeding risk:

Add-on	Dose	Evidence
Rivaroxaban (low dose)	2.5 mg BID + ASA	COMPASS trial: ↓MACE 24%, ↑bleeding; "Dual pathway inhibition"
Ticagrelor	60 mg BID + ASA	PEGASUS trial: ↓MI/stroke in prior MI + DM/renal disease
Clopidogrel	75 mg + ASA (1 year post-PCI)	Standard DAPT post-PCI

2024 ESC CCS (Class IIa): "Adding a second antithrombotic to aspirin for extended secondary prevention should be considered in patients at enhanced ischemic risk and without high bleeding risk."

High Ischemic Risk Features for Extended Therapy - Mnemonic: "DMS-RCC"

D - Diabetes mellitus
M - Multi-vessel CAD
S - Stent thrombosis history / Suboptimal PCI result
R - Recurrent MI
C - CKD (chronic kidney disease)
C - Complex PCI (left main, bifurcation, long lesions)

SECTION 4: CEREBROVASCULAR DISEASE (CVA / TIA / STROKE)

4A. Ischemic Stroke - Acute Phase

Mnemonic: "ACT FAST with ASA, DAPT if Minor, NO ASA after tPA for 24h"

Scenario	Treatment	Class	Source
Acute ischemic stroke (not given tPA)	Aspirin 162-325 mg immediately, then 75-100 mg daily	Class I / Level A	AHA/ASA 2026
After IV tPA	Hold antiplatelet for 24 hours (risk of hemorrhagic transformation)	Class I	AHA/ASA 2026
Minor stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4), within 24h, no thrombolysis	DAPT: ASA + Clopidogrel x 21 days, then single AP	Class I / Level A	AHA/ASA 2026 (CHANCE + POINT trials)
Same as above but within 24-72h	DAPT may still be given (NIHSS ≤5 within 24-72h)	Class IIa	AHA/ASA 2026 (INSPIRES trial)
CYP2C19 loss-of-function carriers (clopidogrel non-responders)	DAPT: ASA + Ticagrelor x 21 days, then ticagrelor monotherapy	Class IIb	AHA/ASA 2026 (CHANCE-2 trial)
Cardioembolic stroke / AF	Anticoagulate (DOAC or warfarin) - NOT antiplatelet as primary strategy	Class I	AHA/ASA 2026

The INSPIRES trial (NEJM 2023) extended the window for DAPT from 24h to 72h post-stroke in NIHSS ≤5 - this is a new addition to AHA/ASA 2026 stroke guidelines

4B. Secondary Prevention of Stroke/TIA

Mnemonic: "CAST - Clopidogrel Alone Surpasses Ticlopidine; ASA+DipyRidamole is an Alternative"

Agent	Indication	Notes
Aspirin 75-100 mg	First-line for noncardioembolic stroke/TIA	Cheapest, effective
Clopidogrel 75 mg	Slightly superior to ASA alone (CAPRIE trial); first-line alternative	Use if ASA intolerant
ASA + Extended-release Dipyridamole (Aggrenox)	Equivalent to clopidogrel; slightly superior to aspirin alone	Headache common side effect
Ticagrelor alone	NOT recommended over ASA (SOCRATES trial negative)	Class III harm (AHA/ASA 2026)
ASA + Clopidogrel long-term	NOT routinely recommended for secondary stroke prevention (MATCH trial: no benefit, more bleeding)	Exception: concurrent ACS or recent stent

4C. Anticoagulation in Stroke

Condition	Anticoagulant	Notes
AF + ischemic stroke/TIA	DOAC preferred over warfarin (Class I)	Start within 2-14 days depending on stroke severity
Mechanical heart valves + stroke	Warfarin (NOT DOAC)	Dabigatran was inferior to warfarin in RE-ALIGN trial
Cryptogenic stroke + PFO	Aspirin OR anticoagulant; consider PFO closure if age <60	Controversial
Cerebral venous sinus thrombosis	UFH or LMWH acutely, then warfarin/DOAC	Even with hemorrhagic infarct
Large atherosclerotic stroke (noncardioembolic)	Antiplatelet NOT anticoagulant	OAC + antiplatelet = increased bleeding, no benefit

What Changed in Stroke Guidelines (2026 AHA/ASA vs. 2019)?

Topic	Previous (2019)	New (2026 AHA/ASA)
DAPT window	Within 24h only (NIHSS ≤3)	Expanded to 72h window (NIHSS ≤5) - INSPIRES trial
Ticagrelor in CYP2C19 non-responders	Not addressed	Class IIb: ticagrelor+ASA for 21d if CYP2C19 LOF carrier
GPIIb/IIIa inhibitors (abciximab)	Uncertain	Now Class III (Harm) - avoid
Tirofiban/Eptifibatide	Uncertain	Class IIb uncertain benefit only
DOAC for non-AF stroke	Not indicated	Still not indicated (NAVIGATE ESUS negative); meta-analysis 2025 confirms adding OAC to antiplatelet = no benefit, more bleeding (PMID: 40219837)

SECTION 5: PERIPHERAL ARTERY DISEASE (PAD)

Based on: 2024 ACC/AHA PAD Guideline (PMID: 38752899) + Braunwald's Heart Disease

Mnemonic: "Single ASA for PAD, Add Clop or Rival if High Risk - AVOID Warfarin alone"

Antithrombotic Strategy in PAD

Scenario	Recommendation	Class	Guideline
Symptomatic PAD (claudication, CLI)	Antiplatelet therapy (ASA 75-100mg OR Clopidogrel 75mg)	Class I	2024 ACC/AHA PAD
Clopidogrel vs ASA in PAD	Clopidogrel marginally superior to ASA alone	Class IIa	Based on CAPRIE
After lower limb revascularization (endovascular)	DAPT (ASA + Clopidogrel) x 1-6 months post-procedure	Class IIa	2024 ACC/AHA PAD
After bypass surgery (venous graft)	Aspirin alone	Class I	2024 ACC/AHA PAD
After bypass surgery (prosthetic graft)	Consider adding clopidogrel to ASA	Class IIa	2024 ACC/AHA PAD
PAD + AF	OAC alone (DOAC preferred) - antiplatelet adds bleeding risk	Class I	2024 ACC/AHA PAD
Chronic limb-threatening ischemia (CLTI) high risk	Rivaroxaban 2.5 mg BID + ASA ("Dual pathway inhibition")	Class IIa	2024 ACC/AHA PAD (VOYAGER PAD trial)
Asymptomatic PAD (ABI <0.9, no symptoms)	Antiplatelet may be used, but benefit-risk less clear	Class IIb	2024 ACC/AHA PAD
Warfarin alone in PAD	NOT recommended	Class III (Harm)	2024 ACC/AHA PAD

What Changed in PAD Guidelines (2024 vs 2016)?

Topic	2016 Guideline	2024 ACC/AHA Update
Rivaroxaban 2.5mg + ASA	Not included	Now Class IIa for high-risk/CLTI (VOYAGER PAD trial 2020)
DAPT post-endovascular	Not well-defined	Now Class IIa for 1-6 months post-endovascular PAD revascularization
Vorapaxar	Mentioned	Now explicitly Class III (Harm) if prior stroke/TIA (absolute CI)
Asymptomatic PAD antiplatelet	Recommended	Now Class IIb - more nuanced; consider risk-benefit
Cilostazol	Mentioned for claudication	Continues Class I for claudication symptom relief (not purely antithrombotic)

SECTION 6: ATRIAL FIBRILLATION - STROKE PREVENTION

Mnemonic: "CHADS2-VASc tells you WHEN; DOAC tells you HOW; HAS-BLED tells you the RISK"

DOAC vs Warfarin

Drug	Dose (non-valvular AF)	Renal adjustment
Dabigatran	150 mg BID (or 110 mg BID if >75y/high bleed risk)	Avoid if eGFR <15
Rivaroxaban	20 mg OD with evening meal	15 mg OD if eGFR 15-49
Apixaban	5 mg BID (2.5 mg BID if 2 of: age ≥80, wt ≤60kg, Cr ≥1.5)	Preferred in CKD
Edoxaban	60 mg OD	30 mg OD if eGFR 15-50, wt ≤60kg, or P-gp inhibitors

DOAC preferred over Warfarin (Class I) in non-valvular AF - all major 2024-2025 guidelines

Warfarin STILL preferred:

Mechanical heart valves (Class I)
Rheumatic mitral stenosis (Class I)
Antiphospholipid antibody syndrome (Class I)

CHA₂DS₂-VASc Scoring Mnemonic - "CHF-HATCH + doubles for Age/Stroke"

Risk Factor	Points
Congestive heart failure	1
Hypertension	1
Age ≥75	2
Diabetes mellitus	1
Stroke / TIA prior	2
Vascular disease (MI, PAD, aortic plaque)	1
Age 65-74	1
Sex category (female)	1
Max	9

When to anticoagulate: Score ≥2 in men, ≥3 in women → Anticoagulate | Score 1 in men → Consider | Score 0 in men → No anticoagulation needed

SECTION 7: VTE PREVENTION & TREATMENT (Brief)

Mnemonic: "LMWH for Hospital, DOAC for Home"

Setting	Preferred Agent
Hospitalized medical patient (immobile)	Enoxaparin 40 mg SC OD or Heparin 5000 U TID
Orthopedic surgery prophylaxis	LMWH or Apixaban/Rivaroxaban
DVT/PE treatment	Rivaroxaban 15mg BID x 3 weeks, then 20mg OD OR Apixaban 10mg BID x 7d then 5mg BID
DVT/PE with cancer	LMWH (dalteparin) OR Rivaroxaban/Apixaban (SELECT-D trial)
Pregnancy + VTE	LMWH (DOACs contraindicated)

SECTION 8: SPECIAL TOPICS - CHANGES IN LATEST GUIDELINES

8A. Aspirin Resistance / CYP2C19 Genotyping

NEW in 2025 CCS/2025 ACC Scientific Statement (PMID: 38104631):

Platelet function testing or CYP2C19 genotyping may guide de-escalation decisions (Class IIb)
Patients with CYP2C19 *2 or *3 loss-of-function: Ticagrelor or Prasugrel preferred over clopidogrel
Unguided de-escalation (empiric switch to clopidogrel) shown to be similarly effective in low-ischemic-risk patients

8B. Antithrombotic Therapy Post-CABG

Mnemonic: "ASA Always After CABG; Add P2Y12 if ACS was the indication"

All patients: Aspirin continued throughout CABG period and restarted immediately post-op (Class I)
Post-CABG for ACS: Add P2Y12 inhibitor when safe post-op (DAPT for 1 year)
Post-CABG for stable CAD: Aspirin alone
NEW (ESC 2025 / TACSI + TOP-CABG trials): Current DAPT recommendations post-CABG are based on "thin evidence" - large RCT data showed de-escalated DAPT (ASA alone from early post-op) had similar graft patency with significantly less bleeding vs full DAPT post-CABG

8C. TAVI (Transcatheter Aortic Valve Implantation)

Based on 2025 Network Meta-Analysis (PMID: 40615791):

If no indication for OAC: Aspirin alone or DAPT (ASA + Clopidogrel) x 3-6 months then ASA alone
If indication for OAC (AF): OAC alone (no antiplatelet added) - reduces bleeding
Dual therapy (OAC + antiplatelet) only if very high thrombotic risk

8D. Left Ventricular Thrombus Post-MI

Based on Meta-Analysis 2024 (PMID: 38412882):

Anticoagulation (warfarin or DOAC) x 3-6 months for confirmed LV thrombus
Prophylactic anticoagulation in anterior STEMI without confirmed LV thrombus: Class IIb - insufficient evidence

MASTER SUMMARY TABLE

Condition	First-line Antithrombotic	Duration	Key Change (Latest)
1° Prevention	ASA only if 10-yr risk ≥10% AND age 40-59	Ongoing	No ASA if age ≥60/70 (ASPREE, ARRIVE)
ACS (acute)	ASA 325 mg + Ticagrelor/Prasugrel	Load immediately	No routine pre-treatment; DAPT de-escalation now explicit
ACS (maintenance)	ASA 81 mg + P2Y12	12 months (default)	ESC: may stop ASA after 1 month, continue P2Y12 alone
Stable CAD	ASA 81 mg	Lifelong	Add rivaroxaban 2.5mg + ASA if high ischemic risk (COMPASS)
Acute minor stroke/TIA	DAPT: ASA + Clopidogrel	21 days, then single AP	Window expanded to 72h (INSPIRES); CYP2C19 testing for ticagrelor
Secondary stroke prevention	Aspirin 75-100 mg OR Clopidogrel	Lifelong	SOCRATES: Ticagrelor alone NOT superior to ASA
AF → stroke prevention	DOAC (apixaban preferred)	Lifelong	DOAC > warfarin; warfarin only for mechanical valves/rheumatic MS
PAD - symptomatic	Clopidogrel OR ASA	Lifelong	Rivaroxaban 2.5mg + ASA now Class IIa in CLTI (VOYAGER PAD)
PAD - post-endovascular	DAPT x 1-6 months	1-6 months	New explicit recommendation in 2024 ACC/AHA PAD
VTE prophylaxis	LMWH or Rivaroxaban/Apixaban	Duration of risk	DOACs now Class I for outpatient VTE treatment
ACS + AF (Triple therapy)	OAC + Clopidogrel (drop ASA at 1-4 weeks)	OAC + P2Y12 x 6-12 mo	Triple therapy ≤1 week; DOAC > warfarin in this setting

MNEMONICS QUICK REFERENCE CARD

"OLD CAP" - Who needs antiplatelet secondary prevention: Old MI, Leg PAD, Diabetes + ASCVD, Coronary stent, Atherosclerotic CVD, Past stroke/TIA
"TaP Beats Clop" - Ticagrelor and Prasugrel > Clopidogrel in ACS/PCI
"DEFAULT 12, BLEED 1-3, EXTEND if DMS-RCC" - DAPT duration in ACS
"TAD-DOWN" - Triple to Double to Alone (for AF + ACS/PCI)
"CHANCE your POINT" - DAPT (ASA+Clop) within 24h for minor stroke/TIA (CHANCE + POINT trials) - 21 days only
"VOYAGER PADs" - Rivaroxaban 2.5mg + ASA for PAD after revascularization (VOYAGER PAD trial)
"COMPASS points to Dual Pathway" - COMPASS trial = Rivaroxaban 2.5mg BID + ASA for stable CAD/PAD secondary prevention
"CHF-HATCH-doubles" - CHA₂DS₂-VASc score (doubles for Age≥75 and Stroke)
"ASPREE killed primary prevention" - ASPREE trial ended routine aspirin in elderly >70 yrs
"DOAC > Warf (except MARVS)" - DOAC preferred except Mechanical valves, APS (antiphospholipid), Rheumatic mitral stenosis, Very specific populations, Severe CKD (eGFR <15)

SOURCES

Harrison's Principles of Internal Medicine, 22nd Edition (2025) - Chapter on Stroke Prevention, Antiplatelet Agents
Goldman-Cecil Medicine International Edition - Chapter 70: Antithrombotic and Antiplatelet Therapy
Fuster & Hurst's The Heart, 15th Edition - Atherothrombosis, Pharmacotherapy
Current Surgical Therapy 14e - Cardiovascular Pharmacology chapter
Adams & Victor's Principles of Neurology, 12th Edition - Antiplatelet Drugs for Secondary Stroke Prevention
2025 ACC/AHA ACS Guideline - J Am Coll Cardiol 2025
2024 ACC/AHA PAD Guideline - Circulation 2024 (PMID: 38752899)
2026 AHA/ASA Acute Ischemic Stroke Guideline
2023 CCS/CAIC Focused Update on Antiplatelet Therapy - Can J Cardiol 2024 (PMID: 38104631)
2026 ACC Scientific Statement on Antiplatelet Therapy in ASCVD

Also tell me what are diferent types of risk assessment scores in different conditions you have discussed and how to remember them for for my PG training and also for my clinical expertise

Reading File

Finding Sources

Searching the Web

risk scores antithrombotic cardiovascular TIMI GRACE CHADSVASC HASBLED ABCD2 CRUSADE ARC-HBR 2024 2025 guidelines clinical use

Also tell me what are diferent types of risk assessment scores in different conditions you have discussed and how to remember them ( with whatever mnemonics are different ways) for my PG training and also for my clinical expertise.

Finding Sources

Searching the Web

TIMI NSTEMI score variables 2025 GRACE ACS risk score variables complete criteria mnemonic

Finding Sources

Searching the Web

ARC-HBR criteria high bleeding risk PCI 2024 PRECISE-DAPT PARIS score DAPT score complete variables

Reading File

Loading Image

Excellent - I have all the data needed. Now compiling the complete, structured answer:

Risk Assessment Scores in Antithrombotic Therapy

Complete PG Guide with Mnemonics | Sources: Harrison's 22E, Braunwald's, Fuster & Hurst, Rosen's EM, Bradley & Daroff's Neurology | 2025 ACC/AHA, 2024 ESC Guidelines

THE BIG PICTURE - ORGANIZING FRAMEWORK

Think of risk scores in antithrombotic therapy as falling into 4 functional categories:

Mnemonic: "BIDE your time before prescribing"

Letter	Category	Purpose	Examples
B	Bleeding risk	Should I give antithrombotic? How long?	HAS-BLED, CRUSADE, ARC-HBR, PRECISE-DAPT, ATRIA, HEMORR²HAGES
I	Ischemic/Thrombotic risk	Who benefits most? Anticoagulate or not?	CHA₂DS₂-VASc, GRACE, TIMI, DAPT Score
D	Diagnostic risk (chest pain)	Is this ACS at all?	HEART Score, EDACS
E	Event-after-event (stroke/TIA)	Recurrence risk?	ABCD2, ABCD3-I, PCE (Primary CVD)

SECTION 1: ACS RISK SCORES

1A. TIMI Risk Score for UA/NSTEMI

Purpose: Predicts 14-day risk of all-cause mortality, new MI, or urgent revascularization

The score has 7 variables, each = 1 point (max score 7)

Mnemonic: "AMERICA" (Developed in the USA - easy to remember)

Letter	Variable	Detail
A	Age ≥65 years	1 point
M	Markers (elevated cardiac biomarkers)	Elevated troponin or CK-MB = 1 point
E	ECG changes (ST deviation ≥0.5mm)	1 point
R	Risk factors ≥3 (HTN, DM, hyperlipidemia, smoking, family hx CAD)	1 point
I	Ischemic events ≥2 in past 24h	Anginal episodes ≥2 in 24h = 1 point
C	Coronary stenosis known ≥50%	Prior cath or documented CAD = 1 point
A	Aspirin use in past 7 days	Aspirin use despite optimal Rx = 1 point

Score Interpretation:

Score	14-day Risk	Action
0-1	5%	Low - may consider early discharge
2	8%	Low-intermediate
3	13%	Intermediate - observe
4	20%	Intermediate-high - early invasive
5	26%	High - early invasive
6-7	41%	Very high - urgent invasive

Clinical tip: TIMI ≥3 = consider early invasive strategy (PCI within 24h)

1B. GRACE Score (Global Registry of Acute Coronary Events)

Purpose: Predicts in-hospital, 6-month, 1-year, and 3-year mortality/death+MI in ACS

Variables (continuous, calculated online/app - 8 parameters):

Mnemonic: "GRACE Has 8 - SHARKCB"

Letter	Variable
S	Systolic blood pressure (lower = worse)
H	Heart rate (higher = worse)
A	Age
R	Renal function (serum creatinine)
K	Killip class (heart failure severity)
C	Cardiac arrest at admission
B	Biomarker (elevated troponin)
+	ST deviation

Score Interpretation (in-hospital mortality for NSTEMI):

Category	Score	In-hospital Mortality
Low	<109	<1%
Intermediate	109-140	1-3%
High	>140	>3%

GRACE vs TIMI - Which to use?

Feature	TIMI	GRACE
Simplicity	Simple, bedside	Requires calculator
Variables	7 binary (yes/no)	8 continuous
Best for	Quick risk triage	More precise mortality prediction
Superior for	NSTEMI triage	STEMI + NSTEMI mortality
2025 ACC/AHA position	Both acceptable	GRACE superior for objective mortality prediction

Key 2025 ACC/AHA Guideline statement: "GRACE Risk Score has been found to be superior to subjective physician assessment for the prediction of death or MI in patients with STEMI or intermediate-risk NSTE-ACS." - Neither score should be used as a diagnostic tool; only for risk stratification in confirmed/suspected ACS.

1C. HEART Score

Purpose: Diagnose and risk-stratify chest pain in the ED - "Is this ACS or can I safely discharge?"

The name IS the mnemonic: H-E-A-R-T (each component scored 0-2, total 0-10)

Letter	Component	0 points	1 point	2 points
H	History	Non-specific	Mixed features	Highly suspicious for ACS
E	ECG	Normal	Non-specific repolarization changes	Significant ST deviation
A	Age	<45 years	45-64 years	≥65 years
R	Risk factors	None	1-2 risk factors	≥3 risk factors OR known ASCVD
T	Troponin	≤ normal limit	1-3x normal	>3x normal

Score Interpretation:

Score	Risk	Action
0-3	Low (~2% MACE)	Discharge safe - consider early discharge
4-6	Moderate (~12% MACE)	Admit - observe and further workup
7-10	High (~65% MACE)	Aggressive workup, likely ACS - activate pathway

HEART vs TIMI vs GRACE - The Quick Comparison:

HEART = ED diagnostic triage (is this ACS?) TIMI = Treatment decisions in confirmed ACS (how aggressive?) GRACE = Mortality prediction in confirmed ACS (how bad is it?)

SECTION 2: BLEEDING RISK SCORES

2A. HAS-BLED Score (Most widely used bleeding score in AF)

Purpose: Estimates major bleeding risk with anticoagulation in AF patients

The name IS the mnemonic:

Letter	Component	Points
H	Hypertension (uncontrolled SBP >160 mmHg)	1
A	Abnormal renal OR liver function (1 each)	1 or 2
S	Stroke history	1
B	Bleeding (prior bleeding history or predisposition)	1
L	Labile INR (on warfarin; TTR <60%)	1
E	Elderly (age ≥65 years)	1
D	Drugs (antiplatelets, NSAIDs) or Alcohol (1 each)	1 or 2

Max score = 9

Score Interpretation:

Score	Bleeding Risk	Annual Bleed Rate	Action
0-1	Low	1-2%	Anticoagulate if stroke risk warrants
2	Moderate	~2%	Consider anticoagulation
≥3	High	≥3.7%	Caution; address modifiable factors; do NOT withhold OAC if stroke risk outweighs

KEY POINT (2024 ESC, Harrison's 22E): A high HAS-BLED score should NEVER be used alone to withhold anticoagulation - it should prompt CORRECTION of modifiable factors (BP control, stop NSAIDs, optimize INR). The score identifies correctable risks, not a contraindication.

Annual stroke (CHA₂DS₂-VASc) vs bleeding (HAS-BLED) rates by score - note how bleeding rate accelerates more steeply at high scores

Figure: Annual stroke % (blue, CHA₂DS₂-VASc) vs major bleed % (red, HAS-BLED) as a function of score. Note the steeper acceleration of bleeding at scores ≥4. Source: Harrison's Principles of Internal Medicine 22E

2B. CRUSADE Score (Bleeding in ACS/PCI)

Purpose: In-hospital major bleeding risk in NSTEMI patients - guides anticoagulant/antiplatelet intensity

Mnemonic: "CRUSADE = 8 variables = CHADS GEH" (overlapping but distinct from cardiac scores)

Variable	Detail
C	Creatinine clearance (↓CrCl = ↑bleeding)
H	Hematocrit (↓Hct = ↑bleeding)
A	Admission heart rate (↑HR = ↑risk)
D	Diabetes mellitus
S	Systolic BP (<90 = ↑risk, but also very high SBP)
+	Gender (female = ↑risk)
+	History of vascular disease
+	Signs of CHF at presentation

Score Interpretation:

Score	Risk Category	Major Bleed Rate
≤20	Very Low	3.1%
21-30	Low	5.5%
31-40	Moderate	8.6%
41-50	High	11.9%
>50	Very High	19.5%

CRUSADE vs HAS-BLED: CRUSADE is for ACS/PCI in-hospital bleeding risk; HAS-BLED is for long-term OAC bleeding risk in AF

2C. ARC-HBR Criteria (Academic Research Consortium - High Bleeding Risk)

Purpose: Standardized definition of High Bleeding Risk (HBR) before PCI/DAPT decisions (2020, validated through 2024)

Definition: ≥1 MAJOR criterion OR ≥2 MINOR criteria = High Bleeding Risk

Mnemonic for MAJOR criteria: "CHAOS A Major Bleed"

Major Criteria	Detail
C	Chronic anticoagulation use (OAC long-term)
H	Hemoglobin <11 g/dL (severe anemia)
A	Active malignancy (within 12 months)
O	OAC required - anticipated long-term
S	Severe CKD (eGFR/CrCl <30 mL/min)
+	Prior ICH or ischemic stroke
+	Non-deferrable major surgery on DAPT
+	Spontaneous bleeding requiring hospitalization/transfusion in past 6 months
+	Thrombocytopenia (<100,000/µL)
+	Liver cirrhosis with portal hypertension

Minor Criteria (need 2 for HBR classification):

Minor Criteria
Age ≥75 years
Moderate CKD (CrCl 30-59 mL/min)
Mild anemia (Hgb 11-12.9g/dL male; 11-11.9g/dL female)
Prior ischemic stroke (not meeting major)
Spontaneous bleeding requiring hospitalization in past 12m (not major)
Long-term NSAID or steroid use

Clinical implication: ARC-HBR = consider shortening DAPT to 1-3 months post-PCI (2024 ESC, 2025 ACC/AHA)

2D. PRECISE-DAPT Score (Newer - Bleeding with DAPT duration)

Purpose: Predicts 1-year out-of-hospital bleeding risk post-PCI; guides DAPT duration choice

Only 5 variables (scored 0-100):

Mnemonic: "ACHeW" - Age, CrCl, Hgb, WBC, prior bleeding

Variable	Component
A	Age
C	Creatinine clearance
H	Hemoglobin
W	White blood cell count
+	Prior Bleeding history

Cutoff: Score ≥25 = High Bleeding Risk → favor short DAPT (3-6 months) Score <25 = Standard/Low Risk → standard 12-month DAPT acceptable

2E. DAPT Score (Balances BOTH bleeding AND ischemic risk for extended DAPT)

Purpose: Predicts NET benefit of extending DAPT beyond 12 months post-PCI

9 variables (the only score that BALANCES both risks):

Mnemonic: "DAPT Score 9 - SAVE DAMS"

Letter	Variable	Points
S	Smoking (active)	+1
A	Age <65	+2; 65-74 = +1; ≥75 = -2
V	Vein graft stenting	-1
E	EF ↓ / CHF at presentation	+2
D	Diabetes mellitus	+1
A	Admission: MI at presentation	+1
M	MI previously (or prior PCI)	+1
S	Stent diameter <3 mm	+1
+	Paclitaxel-eluting stent	+1

Interpretation:

DAPT Score	Action
≥2	Extended DAPT BENEFICIAL (↓ischemic events > ↑bleeding)
<2	Extended DAPT causes more harm (↑bleeding > ↓ischemic events) - do NOT extend

Note: Negative points for age ≥75 and vein grafts reflect the dominant bleeding risk at older age.

SECTION 3: STROKE/AF RISK SCORES

3A. CHA₂DS₂-VASc Score

Purpose: Stroke risk in non-valvular AF - guides OAC decision

The name is the mnemonic (previously shared - now adding the KEY 2024 UPDATE):

⚠️ MAJOR 2024 UPDATE: CHA₂DS₂-VA (ESC 2024 - Sex removed!)

Old Score (ACC/AHA still uses)	New Score (ESC 2024)
CHA₂DS₂-VASc (max 9)	CHA₂DS₂-VA (max 8)
Sex (female) = 1 point	Sex REMOVED
OAC threshold: ≥2 men, ≥3 women	OAC threshold: ≥2 for all (unified)
Anticoagulate ≥2 (men), ≥3 (women)	Anticoagulate ≥2 (everyone)

Why removed? Multiple studies showed sex alone (female) does not independently predict stroke; removing it gives superior or non-inferior discrimination and creates a unified threshold across sexes.

For PG exams: Know BOTH - old CHA₂DS₂-VASc (max 9, sex included) for ACC/AHA; CHA₂DS₂-VA (max 8, no sex) for ESC 2024

Score to Risk conversion (CHA₂DS₂-VASc):

Score	Approx. Annual Stroke Risk (no OAC)
0	~0%
1	~1.3%
2	~2.2%
3	~3.2%
4	~4.0%
5	~6.7%
6	~9.8%
7-9	10-15%+

3B. ABCD2 Score (TIA - predicts short-term stroke risk)

Purpose: Estimates 2-day, 7-day, and 90-day stroke risk after TIA. Used to decide admit vs. discharge.

The name IS the mnemonic: A-B-C-D-2

Letter	Variable	Points
A	Age ≥60 years	1
B	Blood pressure ≥140/90 mmHg	1
C	Clinical features: unilateral weakness = 2; speech disturbance only = 1; other = 0	0-2
D	Duration: ≥60 min = 2; 10-59 min = 1; <10 min = 0	0-2
2	Diabetes mellitus (the "2" in ABCD2 = Diabetes)	1

Total: 0-7 points

Risk Stratification:

Score	Risk	2-day Stroke Risk	Action
0-3	Low	~1%	May consider outpatient workup
4-5	Moderate	~4%	Admit or urgent neurology review
6-7	High	~8%	Immediate admission

AHA/ASA 2026 uses ABCD2 ≥4 to define "high-risk TIA" - this is the threshold for initiating DAPT (ASA + Clopidogrel x 21 days)

IMPORTANT LIMITATION (per Tintinalli's EM, Bradley & Daroff's Neurology): ABCD2 should NOT be used IN ISOLATION to discharge a TIA patient. All TIA patients warrant urgent neuroimaging (MRI DWI) and vascular imaging regardless of ABCD2 score.

Extended versions:

ABCD3: adds dual TIA within 7 days (+2) - max 9
ABCD3-I: adds DWI lesion (+2) and ipsilateral carotid stenosis ≥50% (+2) - max 13. Better predictive accuracy but requires imaging.

SECTION 4: PRIMARY PREVENTION RISK SCORE

4A. Pooled Cohort Equations (PCE) - ASCVD 10-year Risk

Purpose: Primary prevention - should I start aspirin/statin? (the foundational 1° prevention tool)

Variables (calculated online/app - not a simple bedside score):

Mnemonic: "CRASH the Primary Prevention Plan"

Letter	Variable
C	Cholesterol (Total + HDL)
R	Race/ethnicity (African American vs White - different equations)
A	Age and sex
S	Systolic blood pressure (treated vs untreated)
H	History of diabetes + Smoking status

Risk Thresholds for Antithrombotic Decisions:

10-year ASCVD Risk	Aspirin 1° Prevention	Statin
<7.5%	Not recommended	Consider statin if ≥40y + risk factors
7.5-10%	Borderline - discuss with patient	Statin recommended
≥10% (AND age 40-59)	May consider ASA 81mg (Class IIb)	Statin recommended
≥10% (AND age ≥60-70)	NOT recommended - bleeding risk	Statin recommended

SECTION 5: PAD RISK SCORES

5A. Ankle-Brachial Index (ABI) - Not a "score" but a diagnostic/prognostic measure

The fundamental PAD risk number:

ABI Value	Interpretation	Action
>1.4	Non-compressible (calcified) arteries - falsely elevated	Toe-brachial index instead
1.0-1.4	Normal	No PAD
0.9-1.0	Borderline	Repeat with exercise
<0.9	PAD confirmed	Antiplatelet therapy (Class I, 2024 ACC/AHA PAD)
<0.5	Severe PAD / CLTI	Consider rivaroxaban 2.5mg + ASA

Mnemonic: "ABI <0.9 = Anti-platelet you Own" (below 0.9, you own the responsibility to antiplatelet)

SECTION 6: QUICK MASTER TABLE - ALL SCORES AT A GLANCE

Mnemonic to remember ALL score categories: "GAP in BHC Makes Clinical Decisions"

Mnemonic	Score	Condition	What it Decides
G	GRACE	ACS	Mortality risk / invasive urgency
A	AMERICA (TIMI)	NSTEMI/UA	14-day event risk / management
P	PCE (Pooled Cohort)	General population	Start statin/ASA for 1° prevention?
B	BLEEDING: HAS-BLED	AF on OAC	Safe to anticoagulate? How long?
H	HEART Score	ED chest pain	Is this ACS? Safe discharge?
C	CHA₂DS₂-VASc / VA	AF	Start OAC?
+	CRUSADE	NSTEMI/PCI	In-hospital bleeding risk
+	ARC-HBR	Pre-PCI	Shorten DAPT to 1-3 months?
+	PRECISE-DAPT	Post-PCI	DAPT duration (short vs standard)
+	DAPT Score	12 months post-PCI	Extend DAPT beyond 12 months?
+	ABCD2	TIA	Admit or discharge? Start DAPT?
+	ABI	PAD	PAD severity / antiplatelet needed?

SECTION 7: HOW TO RETAIN THESE FOR PG & CLINICAL PRACTICE

7A. Cluster by Purpose ("What question am I answering?")

Think of a patient in front of you - ask these 4 questions in order:

Q1. IS THIS ACS? → HEART Score (ED)
Q2. HOW BAD IS THE ACS? → TIMI (quick) or GRACE (precise mortality)
Q3. SHOULD I ANTICOAGULATE (AF)? → CHA₂DS₂-VASc/VA (stroke) vs HAS-BLED (bleeding)
Q4. HOW LONG SHOULD I GIVE DAPT? → PRECISE-DAPT (before) → DAPT Score (after 12m)
Q5. IS THIS TIA? WILL THEY STROKE? → ABCD2
Q6. IS THIS 1° PREVENTION? → PCE (10-yr ASCVD risk)

7B. "The Patient Journey" Memory Framework

POPULATION → PCE (10-yr risk) → Start 1° prevention?
     ↓
CHEST PAIN IN ED → HEART Score → Low: discharge / High: admit
     ↓
CONFIRMED ACS → TIMI / GRACE → Risk-stratify → Early invasive?
     ↓ (after PCI)
DAPT DURATION: PRECISE-DAPT (<25 vs ≥25) → Short or Standard DAPT?
     ↓ (at 12 months)
EXTEND DAPT? → DAPT Score (<2 vs ≥2) → Stop or extend?
     ↓
PARALLEL TRACK: AF → CHA₂DS₂-VASc + HAS-BLED → Anticoagulate?
     ↓
TIA DETECTED → ABCD2 → Admit + DAPT 21 days?
     ↓
PAD FOUND → ABI → Clopidogrel/ASA ± rivaroxaban 2.5mg

7C. Score-Specific Recall Tricks

Score	Best Memory Hook
TIMI	"AMERICA" - 7 letters, 7 variables, 1 point each
GRACE	"SHARKCB" - 8 variables, needs calculator, beats TIMI for mortality
HEART	The name = The score (H-E-A-R-T, 0-2 each)
CHA₂DS₂-VASc	"CHF-H-A²-D-S²-VA-Sex" - doubles for Age≥75 and Stroke
CHA₂DS₂-VA	2024 ESC = "drop the sex" from VASc
HAS-BLED	The name = The score - modifiable factors = fix them, not a stop sign
ABCD2	"ABCD + diabetes" - the "2" in ABCD2 = Diabetes (D was already used for duration)
ARC-HBR	"1 major OR 2 minor = High Bleed Risk" - major criteria = CHAOS A
PRECISE-DAPT	"ACHeW" - 5 lab/clinical variables only
DAPT Score	"≥2 = extend; <2 = stop" - balances both ischemic AND bleeding
PCE	"CRASH" - 10-yr ASCVD risk calculator

7D. The Critical Cutoffs Table - "Numbers to Tattoo"

Score	Critical Number	Meaning
TIMI NSTEMI	≥3	Early invasive strategy
GRACE	>140	High risk; early catheterization
HEART	≥7	High risk - almost certainly ACS pathway
CHA₂DS₂-VASc	≥2 (men), ≥3 (women)	Start OAC (ACC/AHA)
CHA₂DS₂-VA	≥2 (everyone)	Start OAC (ESC 2024)
HAS-BLED	≥3	High bleeding - fix modifiable factors
ABCD2	≥4	High-risk TIA - DAPT x 21 days
PRECISE-DAPT	≥25	Shorten DAPT to 3-6 months
DAPT Score	≥2	Extend DAPT beyond 12 months
ARC-HBR	1 major or 2 minor	HBR - shorten DAPT
ABI	<0.9	PAD - start antiplatelet
PCE (10-yr ASCVD)	≥10% (age 40-59)	Consider ASA for 1° prevention

SECTION 8: WHAT CHANGED IN SCORING WITH LATEST GUIDELINES

Score	Previous Status	Current Status (2024-2026)
CHA₂DS₂-VASc	Gold standard; sex included; thresholds differ by sex	ESC 2024: Replaced by CHA₂DS₂-VA (sex removed); unified threshold ≥2 for all
ABCD2 alone	Used to decide admission vs discharge in TIA	No longer sufficient alone (Tintinalli's, AHA/ASA 2026); must get DWI MRI regardless of score
TIMI for chest pain (undifferentiated)	Sometimes used in ED	NOT appropriate for undifferentiated chest pain - use HEART Score; TIMI was designed for confirmed/suspected ACS only
HAS-BLED ≥3 = stop OAC	Misapplied - OAC withheld	Corrected: ≥3 = fix modifiable factors; do NOT withhold OAC if stroke risk > bleeding risk
GRACE score	Recommended	2025 ACC/AHA affirms GRACE as superior to physician judgment; but notes insufficient evidence that routine use changes outcomes - use as adjunct not replacement for judgment
CRUSADE	AF bleeding	Still used for NSTEMI in-hospital bleeding; ARC-HBR now preferred for PCI/DAPT decisions
PCE	Standard	Still used; consider adding coronary calcium score (CAC) as a "tie-breaker" for intermediate risk (7.5-20%) - 2023 ACC/AHA prevention guidelines

FINAL STUDY CARD - "7 Scores Every Cardiologist Must Know Cold"

1. CHA₂DS₂-VA(Sc)  →  Stroke risk in AF → Anticoagulate?
2. HAS-BLED        →  Bleeding with OAC → Fix modifiable factors
3. HEART Score     →  ED: Is this ACS?
4. TIMI (AMERICA)  →  ACS: How urgent is intervention? (7 variables)
5. GRACE (SHARKCB) →  ACS: What's the mortality? (8 variables)
6. ABCD2           →  TIA: Admit? Start DAPT?
7. DAPT/ARC-HBR    →  PCI: How long should DAPT last?

Sources:

Harrison's Principles of Internal Medicine 22E (2025) - Stroke Prevention in AF (Fig. 258-3)
Braunwald's Heart Disease - Risk Stratification chapter
Fuster & Hurst's The Heart 15E - AF Classification, Bleeding Risk Scores
Rosen's Emergency Medicine - HEART Score table (Table 64.7)
Bradley & Daroff's Neurology - ABCD2 Score (Table 65.4)
2025 ACC/AHA ACS Guideline - GRACE/TIMI use
ESC 2024 AF Guidelines - CHA₂DS₂-VA adoption
ARC-HBR 2024 Validation - JACC Interventions 2024

This is a shared conversation. Sign in to Orris to start your own chat.